Phase I study of immuno-Cell therapy for advanced and recurrent esophageal squamous cell carcinoma

Phase I study of immuno-Cell therapy for advanced and recurrent esophageal squamous cell carcinoma - Phase I study of immuno-Cell therapy for advanced and recuerent esophageal squamous cell carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007841

Enrollment

Registered

2012-05-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced and recurrent esophageal squamous cell carcinoma

Interventions

Immunocell therapy using activated lymphocytes injections

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Life expectancy of more than 12 weeks 2.Performance status 0-2 3.Age from 20 to 80 years 4.Adequate organ function WBC:>2,000/ mm3 <15,000/mm3 Hb:>7.0 g/dl Plt:>75,000/mm3 AST(GOT),ALT(GPT):<150 IU/l T-Bil:<2.0mg / dl Cr: <2.0mg/dl 5.Written informed consent

Exclusion criteria

Exclusion criteria: 1.patient who has severe complication 2.patient who has bleeding tendency 3.patient who has active infectious disease 4.concomitant treatment with steroids 5.HBs antigen, HCV antibody, HIV antibody or HTLV-1 antibody is positive 6.patient who has activated autoimmune disease 7.patient who was judged to be unsuitable for this clinical trial

Design outcomes

Primary

Measure	Time frame
Safety and responsibility	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026